Australia Breast Cancer Therapeutics Market Report 2022 to 2030

Australia Breast Cancer Therapeutics Market Analysis

$ 3999

Increased incidence of breast cancer and the emergence of novel technologies for breast cancer treatments have propelled the Australian breast cancer therapeutics market from $218 Mn in 2022 to $641 Mn in 2030 with a CAGR of 14.4% for the year 2022-2030. The breast cancer therapeutics market is segmented by therapy, by cancer type, and by distribution channel. Novartis, GlaxoSmithKline Plc, and Kyowa Kirin Co. Ltd are leading players in the Australian breast cancer therapeutics market.

ID: IN10AUPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia

Buy Now

Australia Breast Cancer Therapeutics Market Executive Analysis

Australia's breast cancer therapeutics market size is at around $218 Mn in 2022 and is projected to reach $641 Mn in 2030, exhibiting a CAGR of 14.4% during the forecast period. Estimated health spending for 2022-23 is $105.8 Bn, or 16.8% of all government spending in Australia. M medical services and benefits which mostly consist of Medicare and Private Health Insurance Rebate costs will be accountable for $39.5 Bn, or 37.3% of all health-related costs. The Australian Government will spend $15.3 Bn, or 14.5% of all health expenditures, on health services, including population health, medical research, mental health, blood and blood products, other allied health services, health infrastructure, and payments from the Medical Research Future Fund.

In Australia in 2022, there were more than 20,640 breast cancer diagnoses. Despite an increase in diagnoses, there are more survivors of disease than ever before, and clinical trial research in Australia has significantly contributed to this development. An individual's personal risk of acquiring breast cancer might change depending on a variety of risk factors. This includes inherited genetic conditions like BRCA1 or BRCA2, as well as external conditions including alcohol, smoking, and inactivity.

Australia Breast Cancer Therapeutics Market

Market Dynamics

Market Growth Drivers

One of the main factors propelling the breast cancer therapeutics market growth in Australia over the next few years will be the emergence of targeted therapeutics. Moreover, the Australian market will experience significant demand due to the availability of enhanced diagnostic modalities and the increase in strategic partnerships.

Market Restraints

For certain Australian patients, the high expense of emerging medicines like targeted therapy and immunotherapy which may not be completely covered by the national healthcare program can be a barrier. The bureaucratic bottlenecks in the Australian healthcare system can also hinder the process of receiving payment or accessing specific therapies.

Competitive Landscape

Key Players

Pfizer (AUS)
Roche (AUS)
Sanofi (AUS)
Novartis (AUS)
GlaxoSmithKline Plc
Kyowa Kirin Co. Ltd.
Merck and Co. Inc.

Healthcare Policies and Regulatory Landscape

In Australia, the treatment of breast cancer is supported by a range of national policies and programs. The main policy is the National Breast Cancer Screening Program, which encourages women aged between 50 and 74 years to have a free mammogram every two years. The program aims to detect breast cancer early when it is more treatable. Another policy is the National Cervical, Breast, and Bowel Cancer Screening Program, which provides funding for the delivery of breast cancer screening and follow-up services in Australia.

Reimbursement Scenario

Through its national healthcare program, Medicare, the Australian government also pays for breast cancer treatment. Surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy are all covered under the reimbursement. The rate of reimbursement, however, may change based on the particular treatment. In Australia, state-specific healthcare laws and reimbursement rates for breast cancer treatment may differ, and patients may be required to pay out-of-pocket for specific therapies or services that are not covered by Medicare.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.